The Current Ratio as of April 2025 (TTM) for Oryzon Genomics S.A. (ORYZF) is 0.75

According to Oryzon Genomics S.A.’s latest financial reports and current stock price. The company's current Current Ratio is 0.75. This represents a change of 75.84% compared to the average of 0.42 of the last 4 quarters.

Oryzon Genomics S.A. (ORYZF) Historical Current Ratio (quarterly & annually)

How has ORYZF Current Ratio performed in the past?

The mean historical Current Ratio of Oryzon Genomics S.A. over the last ten years is 2.34. The current 0.75 Current Ratio has changed 3.09% with respect to the historical average. Over the past ten years (40 quarters), ORYZF's Current Ratio was at its highest in in the March 2023 quarter at 1.27. The Current Ratio was at its lowest in in the December 2022 quarter at -1.12.

Oryzon Genomics S.A. (ORYZF) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Oryzon Genomics S.A. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Oryzon Genomics S.A. (ORYZF) Average Current Ratio

How has ORYZF Current Ratio performed in the past?

The current Current Ratio of Oryzon Genomics S.A. (ORYZF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Oryzon Genomics S.A. (ORYZF) Current Ratio vs. Peers

How is ORYZF’s Current Ratio compared to its peers?

Oryzon Genomics S.A.’s Current Ratio is less than Neoleukin Therapeutics, Inc. (15.33), less than Nuvation Bio Inc. (9.04), less than Ovid Therapeutics Inc. (5.32), less than NextCure, Inc. (7.50), less than Connect Biopharma Holdings Limited (11.46), less than Assembly Biosciences, Inc. (2.42), less than Achilles Therapeutics plc (6.04), less than CytomX Therapeutics, Inc. (1.25), less than Instil Bio, Inc. (15.76), less than Adaptimmune Therapeutics plc (2.92), less than Stoke Therapeutics, Inc. (5.81), less than Homology Medicines, Inc. (4.19), less than Black Diamond Therapeutics, Inc. (4.92), less than Harpoon Therapeutics, Inc. (1.89), less than Travere Therapeutics, Inc. (2.08), less than Mineralys Therapeutics, Inc. (14.02), less than Chinook Therapeutics, Inc. (7.59), less than Ikena Oncology, Inc. (11.80), less than Pharvaris N.V. (12.60),

Build a custom stock screener for Oryzon Genomics S.A. (ORYZF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oryzon Genomics S.A. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Oryzon Genomics S.A. (ORYZF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Oryzon Genomics S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.